Search

Your search keyword '"Baldus, Claudia D."' showing total 321 results

Search Constraints

Start Over You searched for: Author "Baldus, Claudia D." Remove constraint Author: "Baldus, Claudia D." Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
321 results on '"Baldus, Claudia D."'

Search Results

1. Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemia

2. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

3. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

5. Prognostic impact of CEBPA mutational subgroups in adult AML

6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

7. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

8. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

9. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

10. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

12. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

13. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

14. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

15. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

16. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

17. Overlapping features of therapy-related and de novo NPM1-mutated AML

18. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

20. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

23. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

24. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

26. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

27. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

28. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.

29. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

30. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

31. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

32. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

33. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study.

34. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

35. In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

37. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia

38. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

39. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia

40. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

43. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

44. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures

46. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

48. Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

49. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

50. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Catalog

Books, media, physical & digital resources